Tagged with

Global Medtech-focused recruitment consultant Ivor Campbell casts his eye over the profiles the global medtech industry needs most today. Campbell argues that while specialist scientists and engineers remain as important as ever, medtech lacks leaders with the commercial acumen and results-driven mindset to turn innovation into profitable and sustainable ventures.  …

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

Mexico The Swiss Chamber in Mexico (SwissCham) represents Swiss companies operating in Mexico, a country that has become Switzerland’s top commercial partner in Latin America. Executive Director Emilia Pfeiffer outlines the role of SwissCham, the robust presence of the Swiss healthcare and life sciences companies in the country, the Chamber’s advocacy…

Mexico The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents more than 60 of the country’s research-based pharmaceutical companies. Executive director Larry Rubin, who took on the association’s leadership six months ago, outlines his priorities, such as building public awareness and stronger relationships with the government. He also weighs in on…

Mexico Gilead’s Mexican affiliate is its largest in the LatAm region, and one that has had an impressive impact as 85 percent of those living with HIV in the country are treated with the company’s therapies. With just seven months behind him as GM, Arturo de la Rosa explains what is…

China Adept at identifying promising biotechs, Qiming Venture Partners-backed companies saw no less than eight IPOs last year. Managing Partner Nisa Leung provides an update on the firm’s activities in light of current China-US geopolitical tensions and the evolving business development models that have become more focused on licensing innovative drugs…

Hong Kong Professor at the Chinese University of Hong Kong since 1993 and pioneer in studying the causes of stroke in China, Lawrence Wong comments on neurology advancements over the past 30 years; the increasing number of Alzheimer’s cases amongst Asian populations, and the need to go from a symptomatic approach to…

China Coming to ALK China from an extensive and varied career, Xian Ji has helped build a new strategy for the allergy specialist’s local affiliate, which has led to quintupled business revenues. She discusses how ALK China has attracted new talent, the strong unmet medical need allergy immunotherapy (AIT) represents in…

Saudi Arabia Noncommunicable diseases are the leading cause of death and disability worldwide, accounting for 74 percent of all deaths and more than three out of four years lived with a disability. These chronic conditions – which cannot be transmitted from person to person and often require long-term or lifelong care –…

Europe Last year the European Commission (EC) came out with a proposal to reform the EU’s core pharmaceutical legislation, aiming to address affordability, accessibility, and availability, among other objectives. One of the key changes proposed was reducing the EU’s baseline regulatory data protection (RDP) timeline, a plan that pleased the generics…

Europe Vikas Krishan, chief digital business officer at the global data and digital engineering solutions firm Altimetrik, outlines the implications of the European Union’s forthcoming AI Act for the pharma industry and urges for the need to adopt a proactive approach in evaluating AI roadmaps and governance.   The pharmaceutical industry’s…

Mexico Vincenzo D’Elia discusses the creation of Alfasigma’s Mexican affiliate – now solidly established after 14 years – and the company’s local strategy and market approach. He emphasizes the importance of understanding market dynamics for localized portfolio selection, highlights the company’s decision not to engage in government contracts, and comments on…